Search Results

Mycovia Pharmaceuticals, Inc. today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC).

Mycovia Pharmaceuticals, Inc. today announced that its partner Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) has published its phase 3 study evaluating the efficacy and safety of VIVJOA® (oteseconazole) capsules versus fluconazole in the treatment of severe vulvovaginal candidiasis (VVC) in Chinese women in the journal Antimicrobial Agents and Chemotherapy.

HUTCHMED Limited announces the initiation of a Phase II/III trial to evaluate the efficacy of a combination of the HUTCHMED drug candidate surufatinib, the Jiangsu Hengrui Pharmaceuticals Co., Ltd PD-1 antibody camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma in China.

Mycovia Pharmaceuticals, Inc. today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) received approval in June from the National Medical Products Administration for Oteseconazole Capsules, an azole antifungal, indicated for the treatment of severe vulvovaginal candidiasis (VVC).

Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Elevar Therapeutics, Inc. announced a global licensing agreement that grants Elevar rights to commercialize and develop Hengrui Pharma’s anti-PD-1 antibody camrelizumab in combination with rivoceranib for unresectable hepatocellular carcinoma worldwide, excluding Greater China Region and Korea.

Elevar Therapeutics, Inc. and Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced a global licensing agreement that grants Elevar rights to commercialize and develop Hengrui Pharma’s anti-PD-1 antibody camrelizumab in combination with rivoceranib for unresectable hepatocellular carcinoma worldwide, excluding Greater China Region and Korea.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd announced a licensing agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, for its next-generation potent and selective PARP1 inhibitor, HRS-1167.

Innovative vaccine company Recbio announced its latest progress and annual results for 2023.

Teva Pharmaceutical Investments Singapore Pte Ltd, a subsidiary of Teva Pharmaceutical Industries Ltd. and Jiangsu Nhwa Pharmaceutical Co., Ltd announced it formed a partnership for the marketing and distribution of Teva’s AUSTEDO for the treatment of neurodegenerative and movement disorders - chorea associated with Huntington’s disease and tardive dyskinesia in adults.